Palatin completes enrollment in Phase 3 dry eye study (PL9643); 570 patients enrolled, topline expected Q4 2023

PALATIN TECHNOLOGIES INC

PL9643 MELODY-1 Phase 3 study enrolled 570 patients with moderate-to-severe dry eye disease.
Topline data anticipated by end of Q4 2023; interim analysis of first 120 patients showed safety and efficacy.
Assuming positive results, NDA submission to FDA expected mid-2025 after two more Phase 3 studies in 2024-2025.
Company highlighted PL9643's novel mechanism of action and differentiated profile vs. current DED treatments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.